AstraZeneca
AZN
1,495 hedge funds and large institutions have $196B invested in AstraZeneca in 2026 Q2 according to their latest regulatory filings, with 262 funds opening new positions, 521 increasing their positions, 489 reducing their positions, and 120 closing their positions.
118% more first-time investments, than exits
New positions opened: 262 | Existing positions closed: 120
29% more capital invested
Capital invested by funds: $152B → $196B (+$44.1B)
8% more funds holding
Funds holding: 1,383 → 1,495 (+112)
7% more repeat investments, than reductions
Existing positions increased: 521 | Existing positions reduced: 489
15% less funds holding in top 10
Funds holding in top 10: 72 → 61 (-11)
24.42% less ownership
Funds ownership: 24.42% → 0% (-24%)
42% less call options, than puts
Call options by funds: $704M | Put options by funds: $1.21B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$900M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$546M |
| 3 |
CCM
Causeway Capital Management
Los Angeles,
California
|
+$364M |
| 4 |
AAMU
AEGON Asset Management (UK)
Edinburgh,
United Kingdom
|
+$358M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$341M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$540M |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$318M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$257M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$241M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$229M |
AZN Hedge Fund Activity: Q2 2026 in Review
1,495 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2026, worth a combined $196B — up 29% from $152B a quarter earlier.
Buyers outnumbered sellers: 262 funds opened new AZN positions and 120 closed out — a net gain of 142 holders — while 521 added to existing stakes and 489 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $900M. The largest seller was T. Rowe Price Associates, cutting an estimated $540M.
- 1,495 institutional investors held AstraZeneca (AZN) as of Q2 2026, up from 1,383 in Q1 2026.
- Funds reported $196B of AstraZeneca stock for Q2 2026, up 29% quarter-over-quarter.
- 262 funds opened new AstraZeneca positions in Q2 2026 and 120 closed out, a net change of +142 holders.
- The largest AstraZeneca buyer in Q2 2026 was Wellington Management Group, an estimated $900M added.
- The largest AstraZeneca seller in Q2 2026 was T. Rowe Price Associates, an estimated $540M sold.
Based on aggregated 13F filings for Q2 2026.